Summary:
A PHASE Ib, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, MULTIPLE ASCENDING−DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS BFKB8488A IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Qualified Participants Must:
• Be between 18 and 75 years of age
•
Have a BMI between 27 and 40
•
Have Type II diabetes for at least 6 months
•
Hba1c between 6.8% and 9.0%
•
Type II diabetes can be controlled by diet or medication